Aandeel PHGE BIOMX INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen BiomX Inc.

Aandelen

PHGE

US09090D1037

Beurs gesloten - Nyse
Andere beurzen
 22:10:00 21-06-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
0,3328 USD +0,45% Intraday-grafiek van BiomX Inc. -2,12% +18,86%
21/05 Transcript : BiomX Inc., Q1 2024 Earnings Call, May 21, 2024
20/05 BiomX Inc. rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024 CI

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Intelligent Bio Solutions Inc. (NASDAQ: INBS) Advancing US FDA Process, Featured Among Top Health Care Movers
BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024
BiomX : Introduction
BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates
BiomX Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
BiomX to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 21, 2024
BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases
BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)
BiomX Announces the Appointment of Susan Blum to its Board of Directors
Biomx Inc. Appoints Susan Blum to Its Board of Directors and Member and Chair of the Audit Committee of the Board
BiomX : Introduction
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
BiomX Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024
Biomx Inc. Announces Board Changes
BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing
BiomX Inc. announced that it has received $50.013969 million in funding from Deerfield Management Company, LLC, AMR Action Fund GP, LLC, Cystic Fibrosis Foundation, Nantahala Capital Management, LLC, OrbiMed Advisors LLC
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers PHGE
  4. Nieuws BiomX Inc.
  5. Andere talen